Giuseppe Barone

6PUBLICATIONS
121CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory Neuroblastoma.

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Jan 08, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Lucas Moreno, Rebekah Weston, Cormac Owens

|Feb 06, 2021
Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell.

Gerda Kildisiute, Waleed M Kholosy, Matthew D Young

|Nov 26, 2020
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.

Karin Straathof, Barry Flutter, Rebecca Wallace

|Dec 07, 2019
Embryonal precursors of Wilms tumor.

Tim H H Coorens, Taryn D Treger, Reem Al-Saadi

Pageof 1

Frequent Collaborators

3 joint publications

Karin Straathof

3 joint publications

Dyanne Rampling

3 joint publications

John Anderson

2 joint publications

Catriona Duncan